We found that Nrf2 and its target genes, including HO-1 and NQO-1, were upregulated in cisplatin-resistant ovarian cancer cells, and Nrf2, the main regulator of HO-1, was of great importance for the development of cisplatin resistance in ovarian cancer [172,173,174]. This evidence concerns the gene NFE2L2 and ovarian carcinoma.